DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
2015; Massachusetts Medical Society; Volume: 373; Issue: 18 Linguagem: Inglês
10.1056/nejmoa1506859
ISSN1533-4406
AutoresJoaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Pérez-López, Daniel Nava Rodrigues, Dan R. Robinson, Aurelius Omlin, Nina Tunariu, Gunther Boysen, Núria Porta, Penny Flohr, Alexa Gillman, Ines Figueiredo, Claire Paulding, George Seed, Suneil Jain, Christy Ralph, Andrew Protheroe, Syed A. Hussain, Robert J. Jones, Tony Elliott, Ursula McGovern, Diletta Bianchini, Jane Goodall, Zafeiris Zafeiriou, Chris T. Williamson, Roberta Ferraldeschi, Ruth Riisnaes, Bernardette Ebbs, Gemma Fowler, Desamparados Roda, Wei Yuan, Yi‐Mi Wu, Xuhong Cao, Rachel Brough, Helen N. Pemberton, Roger A’Hern, Amanda Swain, Lakshmi P. Kunju, Rosalind A. Eeles, Gerhardt Attard, Christopher J. Lord, Alan Ashworth, Mark A. Rubin, Karen E. Knudsen, Felix Y. Feng, Arul M. Chinnaiyan, Emma Hall, Johann S. de Bono,
Tópico(s)Cell death mechanisms and regulation
ResumoProstate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition with olaparib.
Referência(s)